Search

Nucleic Acid Analytics for Live Biotherapeutic Products

Creative Biolabs provides integrated nucleic acid analytics for live biotherapeutic products, connecting strain identity, genetic stability, copy number, and residual nucleic acid measurements into a consistent quality evidence package. From fit-for-purpose DNA/RNA extraction through qPCR, ddPCR, and sequencing, our team helps analytical development, QC, and CMC groups select methods, interpret results, and define next-step specifications.

Building Coherent Molecular Evidence for LBP Quality

Live biotherapeutic developers must prove that the intended strain is present, its defining genetic features remain intact, and nucleic acid impurities are controlled across materials and process stages. Yet extraction recovery, assay specificity, genome complexity, matrix inhibition, and reference-standard choices can make results from different methods difficult to compare or defend as one quality story.

Analytical development, strain characterization, QC, and CMC teams therefore need a coordinated strategy that assigns the right molecular method to each question and links the resulting evidence to release, stability, and characterization decisions. Creative Biolabs provides nucleic acid analysis services that integrate sample preparation, targeted quantification, sequencing, data interpretation, and method lifecycle planning for live biotherapeutic programs.

One analytical framework, distinct questions.

Identity, copy number, genetic stability, expression, and residual nucleic acids require purpose-built controls and acceptance logic, but their outputs should support one traceable product-quality narrative.

Integrated Nucleic Acid Analytics Services for LBP Programs

We design a fit-for-purpose molecular testing plan around the sample, biological question, development stage, and intended use of each result, then connect individual assays into an interpretable evidence package.

Inputs

Representative Materials

Cell banks, isolates, fermentation samples, drug substance, formulated drug product, process intermediates, stability pulls, and matrix controls.

Analytical Engine

Orthogonal Molecular Methods

DNA/RNA extraction, electrophoresis, PCR, qPCR, ddPCR, 16S rRNA sequencing, targeted or whole-genome sequencing, RNA sequencing, and bioinformatics.

Outputs

Decision-Ready Evidence

Traceable identity conclusions, quantitative results, variant summaries, comparability assessments, method records, gap findings, and specification recommendations.

DNA and RNA Extraction Strategy

We develop or adapt extraction workflows for organism type and product matrix, with attention to cell-wall disruption, nucleic acid recovery, inhibitor removal, integrity, purity, and downstream assay compatibility.

Decision value: reduce sample-preparation bias before method comparison or transfer.

Strain Identity and Product Purity

PCR-based markers, amplicon sequencing, 16S rRNA analysis, targeted panels, and genome-level comparisons can distinguish genus, species, subspecies, or strain and detect unexpected microbial content.

Decision value: establish identity logic appropriate to the required resolution.

qPCR and ddPCR Quantification

Target-specific qPCR or ddPCR supports relative or absolute quantification of strain markers, construct elements, genes of interest, and residual nucleic acids. We address specificity, dynamic range, inhibition, controls, normalization, and units.

Decision value: obtain sensitive, reproducible measurements matched to the question.

Copy Number and Genetic Stability

Copy-number assays and sequence comparisons can track plasmid retention, integrated constructs, target loci, or genome-level changes across passages, banks, process conditions, and stability timepoints.

Decision value: link molecular change monitoring to strain and product control.

Transcriptomics and Targeted RNA Analysis

qRT-PCR, RNA sequencing, and focused expression panels can characterize transcriptional responses, confirm pathway activity, or compare conditions. Design considers RNA stabilization, quality, normalization, replication, and interpretation limits.

Decision value: connect RNA-level evidence to mechanism or process understanding.

Residual Nucleic Acid Testing

Matrix-appropriate qPCR or ddPCR methods can quantify residual host, plasmid, vector, or other process-related nucleic acids. We help define analyte scope, pretreatment, recovery controls, sensitivity, and reporting basis.

Decision value: convert impurity questions into measurable control strategies.

Method Development, Qualification, and Validation Support

Depending on development stage and intended use, we can support feasibility, optimization, qualification, or validation planning. Performance evaluation may include specificity, recovery, precision, linearity, range, sensitivity, robustness, system suitability, sample stability, and predefined acceptance criteria, with documentation prepared for review and transfer.

  • 01Risk-based parameter selection
  • 02Controls and reference strategy
  • 03Acceptance-criteria rationale
  • 04Method and report documentation

LBP Nucleic Acid Testing Deliverables and Decision Support

Deliverables are scaled to project stage and intended use so teams can act on the data, trace the reasoning, and plan the next analytical milestone.

Deliverable What It Contains Program Value
Analytical Strategy and Gap Map Quality questions, existing evidence, method-to-attribute mapping, sample and control needs, and prioritized gaps. Aligns analytical development, QC, CMC, and strain teams around one plan.
Method Protocol and Performance Package Sample preparation, reagents, instruments, controls, calculations, suitability rules, performance data, and deviations where applicable. Supports repeatable execution, review, qualification, validation, or transfer.
Identity or Stability Evidence Report Sequence QC, alignment or taxonomic outputs, marker results, copy-number data, variant summaries, and conclusion logic. Creates a traceable molecular record across banks, batches, passages, or timepoints.
Specification and Next-Step Recommendations Attribute definitions, reporting units, preliminary limits or ranges, monitoring frequency, and data needed to refine criteria. Turns analytical observations into practical control and development decisions.

Nucleic Acid Analytics Workflow for Live Biotherapeutics

A gated workflow keeps assay selection, controls, performance expectations, and interpretation aligned with the question the data must answer.

1

Define the Question

Clarify attribute, sample, decision, stage, resolution, and sensitivity.

2

Design the Method

Select extraction, platform, targets, standards, controls, and acceptance logic.

3

Establish Performance

Evaluate suitability, inhibition, specificity, precision, recovery, range, and sensitivity.

4

Test and Interpret

Run representative samples, review controls, analyze results, and investigate discordance.

5

Report and Advance

Deliver conclusions, limitations, method records, gap findings, and next steps.

Published Data Supporting Molecular Identity Analytics

Recent research applied whole-metagenome shotgun sequencing, taxonomic classification, genome reconstruction, and orthogonal cell analysis to characterize complex probiotic products. The work demonstrates why a single assay rarely answers every identity and quality question: sequence reads support compositional assessment, reconstructed genomes add organism-level resolution, and complementary measurements help interpret abundance and product integrity. This evidence is directly relevant to live biotherapeutic analytics because strain identity, purity, and quantitative claims must be linked through appropriate methods and controls.

The figure shows an integrated path from product sampling through sequencing, classification, genomic reconstruction, enumeration, and viability assessment. Its central lesson is analytical coordination: outputs become more useful when methods are selected as parts of one evidence framework rather than as isolated tests. Creative Biolabs supports this approach by matching DNA and RNA workflows, qPCR or ddPCR, sequencing, and data review to each program's quality attributes, matrices, development stage, and decision needs.

Integrated whole-metagenome sequencing and cell analysis workflow for probiotic product identity. (OA Literature)
Fig.1 Schematic representation of the probiogenomics-based approach named Probiotic Identity Card (PIC). 1,2

Why Creative Biolabs for LBP Nucleic Acid Analytics

Our platform combines microbial product experience, multiple molecular technologies, and development-focused reporting so each result advances a defined quality decision.

01

Fit-for-Purpose Design

The method begins with the product question, required resolution, matrix, and intended use of the result.

02

Orthogonal Capabilities

PCR, qPCR, ddPCR, sequencing, electrophoretic assessment, and bioinformatics support complementary evidence.

03

Stage-Appropriate Rigor

Exploratory work, optimization, qualification, validation support, and transfer planning can scale with program maturity.

04

Actionable Reporting

Reports connect controls, results, limitations, specification considerations, and next steps for cross-functional review.

Frequently Asked Questions

The choice depends on the required taxonomic resolution, strain complexity, available reference sequence, matrix, and intended use. A species-level 16S rRNA result may be suitable for one question but insufficient for closely related strains. We can combine strain-specific PCR, targeted sequencing, or genome-level comparison when greater discrimination is needed.

Standard DNA-based amplification measures target nucleic acid and does not by itself prove viability. Depending on the program, sample pretreatment, RNA targets, culture-based results, or another orthogonal approach may be needed. We define the claim first and select methods that support an appropriate interpretation.

Targeted qPCR or ddPCR can monitor defined loci or construct copy number, while sequencing can evaluate broader changes. A stability plan should specify passages or timepoints, comparators, sensitivity expectations, variant review rules, and how observed changes will be assessed alongside phenotype or function.

Useful inputs include strain and construct information, target sequences, sample types, expected concentrations, matrix details, existing protocols and data, reference materials, proposed reporting units, development stage, and the decision the result must support. Missing inputs can be identified during scoping.

Yes. We can help frame attribute definitions, reporting units, assay suitability, preliminary limits or ranges, and the additional data needed to refine criteria. Recommendations are based on the product, method capability, available batch history, development stage, and intended control strategy.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure (Creative Biolabs Original)

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure (Creative Biolabs Original)

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure (Creative Biolabs Original)

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video (Creative Biolabs Original)

Live Biotherapeutics - Creative Biolabs - Video

References

  1. Lugli, Gabriele Andrea, et al. "The Probiotic Identity Card: A novel 'probiogenomics' approach to investigate probiotic supplements." Frontiers in Microbiology 12 (2022): 790881. https://doi.org/10.3389/fmicb.2021.790881
  2. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Creative Biolabs-Live Biotherapeutics


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us
Solutions

Copyright © 2026 Creative Biolabs. All Rights Reserved.

Inquiry Basket